News & Blog

News & Blog

  • Reset
Blog | Jun 17 2024

Meet the Community – Kyle Duhon

Community
Blog | Jun 10 2024

Meet the Community – Hayden Clay Rogers

Community
Blog | Jun 3 2024

Meet the Community – Anita Gracey

Community
News | May 30 2024

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Industry News
Blog | May 28 2024

Meet the Community – Tyler Ray Rogers

Community
News | May 20 2024

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open l...

Industry News | Partner News
Blog | May 20 2024

Meet the Community – Bernhard “Bernie” Metz

Community
Blog | May 13 2024

2024 Baton Rouge Research Reception Recap

Events
News | May 8 2024

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Industry News
Blog | May 2 2024

Meet the Community – Jason Drake

Community
News | Apr 25 2024

Astellas shares that US FDA cleared their IND with Fast Track designation for Phase 1 trial of their investigational gene therapy for the treatment of cardiomyopathy in FA

In a communication to FARA and the FA Community, Astellas shared that the US FDA has cleared their Investigational New Drug with a fast ...

Industry News
News | Apr 22 2024

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Industry News